Well not bad at all considering the downfall we had seen during FDA turmoil. Very much welcome numbers. IT shows consistency and help improve confidence in script. Combining it with another launch if lenzetto product, it must be a BUY.
- Forums
- ASX - By Stock
- ACR
- Q4 Axiron Sales
Q4 Axiron Sales, page-7
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.4¢ |
Change
-0.001(2.22%) |
Mkt cap ! $12.79M |
Open | High | Low | Value | Volume |
4.5¢ | 4.5¢ | 4.4¢ | $10.91K | 243.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 82022 | 4.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.6¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 82022 | 0.044 |
2 | 547000 | 0.043 |
2 | 94414 | 0.041 |
5 | 442500 | 0.040 |
1 | 78000 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.046 | 10000 | 1 |
0.048 | 44500 | 3 |
0.049 | 120000 | 1 |
0.052 | 103000 | 2 |
0.055 | 120542 | 1 |
Last trade - 15.11pm 15/11/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online